T9G Stock Overview
Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of medicines for oncologic and dermatologic diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Vidac Pharma Holding Plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.20 |
52 Week High | €1.63 |
52 Week Low | €0.19 |
Beta | 0 |
1 Month Change | -35.48% |
3 Month Change | -80.20% |
1 Year Change | -82.61% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -82.61% |
Recent News & Updates
Recent updates
Shareholder Returns
T9G | DE Biotechs | DE Market | |
---|---|---|---|
7D | 5.3% | 1.6% | -1.4% |
1Y | -82.6% | -21.6% | 2.2% |
Return vs Industry: T9G underperformed the German Biotechs industry which returned -21.6% over the past year.
Return vs Market: T9G underperformed the German Market which returned 2.2% over the past year.
Price Volatility
T9G volatility | |
---|---|
T9G Average Weekly Movement | 10.7% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: T9G's share price has been volatile over the past 3 months.
Volatility Over Time: T9G's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2021 | n/a | n/a | www.vidacpharma.com |
Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of medicines for oncologic and dermatologic diseases. The company is developing VDA-1102 ointment, an anti-neoplastic agent that is in Phase 2 clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells. It is also developing VDA-1102 IV, an anti-neoplastic agent; and VDA-1275, a potent small molecule new chemical entity that are in preclinical stage for use in the treatment of solid tumors.
Vidac Pharma Holding Plc Fundamentals Summary
T9G fundamental statistics | |
---|---|
Market cap | €10.33m |
Earnings (TTM) | €0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs T9G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
T9G income statement (TTM) | |
---|---|
Revenue | €0 |
Cost of Revenue | €0 |
Gross Profit | €0 |
Other Expenses | €0 |
Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did T9G perform over the long term?
See historical performance and comparison